Related Experiment Video

Updated: Oct 11, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma

Shansa Pranami E Jayaweera1, Sacheela Prasadi Wanigasinghe Kanakanamge1, Dharshika Rajalingam1

  • 1Department of Chemistry, Faculty of Science, University of Colombo, Colombo, Sri Lanka.

Frontiers in Oncology
|December 3, 2021
PubMed

Insights

Carfilzomib is a proteasome inhibitor that offers improved treatment options for multiple myeloma by irreversibly targeting proteasomes, potentially overcoming resistance seen with earlier drugs.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • The proteasome is vital for intracellular protein degradation, regulating cell survival and progression.
  • Cancer cells, particularly multiple myeloma (MM), exhibit heightened dependence on the ubiquitin proteasome pathway (UPP).
  • Proteasome inhibitors represent a key therapeutic strategy for human cancers like MM.

Purpose of the Study:

  • To review the biochemical properties and mechanism of action of carfilzomib.
  • To analyze the toxicity profile and clinical trial data for carfilzomib.
  • To highlight carfilzomib's potential to overcome bortezomib-related toxicities and resistance.

Main Methods:

  • Literature review of biochemical properties.
  • Analysis of preclinical and clinical trial data.
  • Comparison of carfilzomib with other proteasome inhibitors.

Main Results:

  • Carfilzomib is a second-generation proteasome inhibitor with irreversible binding.
  • It demonstrates efficacy in treating relapsed and/or refractory multiple myeloma.
  • Carfilzomib may offer an improved toxicity and resistance profile compared to bortezomib.

Conclusions:

  • Carfilzomib is an important therapeutic option for multiple myeloma patients.
  • Its irreversible binding mechanism addresses limitations of first-generation inhibitors.
  • Further research and clinical application are warranted for carfilzomib in MM treatment.
Keywords:
anti-tumor effectcarfilzomibcombination therapymultiple myelomaproteasome inhibitors

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.6K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
285
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
257
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K
The Proteasome02:18

The Proteasome

3.7K